Anxiety to SARS-CoV-2 vaccine in patients with autoimmune liver disease and effect of information sharing

Anxiety to SARS-CoV-2 vaccine in patients with autoimmune liver disease and effect of information sharing - Anxiety to SARS-CoV-2 vaccine in patients with autoimmune liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044128

Enrollment

Registered

2021-05-07

Start date

2021-05-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune liver disease

Interventions

Providing information about COVID19 and vaccines to SARS-CoV-2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with autoimmune liver disease With informed assent to be participant in this study

Exclusion criteria

Exclusion criteria: Without informed assent to be participant in this study

Design outcomes

Primary

Measure	Time frame
Information sharing improves objective parameter of anxiety to the vaccination.	—

Secondary

Measure	Time frame
Effect of information sharing to decision of vaccine receiving.	—

Countries

Japan

Contacts

Public ContactKeisuke Kakisaka

Iwate Medical University Division of Hepatology, Department of Internal Medicine

keikaki@iwate-med.ac.jp0196515111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026